MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer (mUC) (Alliance A032001)

被引：0

作者：

Gupta, Shilpa

Ballman, Karla V.

Galsky, Matt D.

Morris, Michael J.

Chen, Ronald C.

Chan, Timothy A.

Dercle, Laurent

Wen, Yujia

Sridhar, Srikala S.

Yen, Aihua Edward

Grivas, Petros

Tan, Alan

Baghaie, Shiva

Rosenberg, Jonathan E.

机构：

[1] Cleveland Clin Fdn, Taussig Canc Inst, Cleveland, OH USA

[2] New York Presbyterian Hosp, Weill Cornell Med, New York, NY USA

[3] Tisch Canc Inst, New York, NY USA

[4] Mem Sloan Kettering Canc Ctr, Div Solid Tumor Oncol, New York, NY USA

[5] Univ Kansas, Kansas City, KS USA

[6] Mem Sloan Kettering Canc Ctr, New York, NY USA

[7] Columbia Univ, New York Presbyterian Hosp, Dept Radiol, Med Ctr, New York, NY USA

[8] Univ Chicago, Chicago, IL USA

[9] Princess Margaret Canc Ctr, Canc Clin Res Unit, Toronto, ON, Canada

[10] Baylor Coll Med, Houston, TX USA

[11] Univ Washington, Seattle, WA USA

[12] Fred Hutchinson Canc Res Ctr, Seattle, WA USA

[13] Premier Onc Hem Assoc, Chicago, IL USA

[14] Alliance Clin Trials Oncol, Chicago, IL USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

基金：

美国国家卫生研究院;

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS4607

引用

页数：1

共 50 条

[1] MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).
Gupta, Shilpa
Ballman, Karla V.
Galsky, Matt D.
Morris, Michael J.
Sridhar, Srikala S.
Chen, Ronald C.
Chan, Timothy An-Thy
Wen, Yujia
Grivas, Petros
Tan, Alan
Baghaie, Shiva
Rosenberg, Jonathan E.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[2] MAIN-CAV: Phase III randomized trial of maintenance cabozantinib (CABO) and avelumab (Av) vs Av after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).
Gupta, Shilpa
Ballman, Karla V.
Apolo, Andrea B.
Sridhar, Srikala S.
Chen, Ronald C.
Wen, Yujia
Yen, Aihua Edward
Grivas, Petros
Tan, Alan
Baghaie, Shiva
Galsky, Matt D.
Morris, Michael J.
Rosenberg, Jonathan E.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS714 - TPS714
[3] Efficacy of talazoparib and avelumab as a maintenance treatment in patients with advanced/metastatic urothelial carcinoma (mUC) whose disease did not progress after a first-line platinum-based chemotherapy (PBCT): The GETUG-TALASUR trial
Coquan, E.
Boughalem, E.
Pouessel, D.
Lequesne, J.
Calcagno, F.
Grellard, J-M.
Christy, F.
Mahammedi, H.
Ladoire, S.
Borchiellini, D.
Leman, R.
Bazille, C.
Fontugne, J.
Crouzet, L.
Flechon, A.
Serrate, C.
Gravis, G.
Clarisse, B.
Vuillemin, A. Thiery
Lobbedez, F. Joly
ANNALS OF ONCOLOGY, 2024, 35 : S1144 - S1145
[4] Trial in progress: A phase 2, randomized, open-label study of trilaciclib with first-line, platinum-based chemotherapy and avelumab maintenance in untreated patients with locally advanced or metastatic urothelial carcinoma (PRESERVE 3).
Sonpavde, Guru P.
Grivas, Petros
Milowsky, Matthew I.
Galsky, Matt D.
Malik, Rajesh K.
Beelen, Andrew Paul
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[5] A phase II trial with copanlisib plus avelumab as maintenance therapy for metastatic bladder cancer after platinum-based chemotherapy.
Farrukh, Hizra
Zhu, Zheng
Zhu, Shaoming
Montgomery, Robert Bruce
Meeks, Joshua J.
VanderWeele, David James
Wong, Yu-Ning
Lew, Robert A.
Pan, Chong-xian
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[6] Real world outcomes for maintenance avelumab treatment in locally advanced/metastatic urothelial cancer after platinum-based chemotherapy.
Rehan, Ahmed
Qureshi, Muneeb
Aydin, Sabin Goktas
O'Connor, Kate
Serra, Maria
Charnley, Natalie
Spurgeon, Laura
Muazzam, Iqtedar
Bansal, Vikram
Vasudev, Naveen
Coe, Faye
Kagzi, Mohammed Mubashir
Din, Omar
Leach, Diane
Hubbard, Rachel
Catto, James W. F.
Hussain, Syed A.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL)
[7] Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100
Moehler, Markus
Dvorkin, Mikhail
Boku, Narikazu
Ozguroglu, Mustafa
Ryu, Min-Hee
Muntean, Alina S.
Lonardi, Sara
Nechaeva, Marina
Bragagnoli, Arinilda C.
Coskun, Hasan S.
Cubillo Gracian, Antonio
Takano, Toshimi
Wong, Rachel
Safran, Howard
Vaccaro, Gina M.
Wainberg, Zev A.
Silver, Matthew R.
Xiong, Huiling
Hong, Janet
Taieb, Julien
Bang, Yung-Jue
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (09) : 966 - 977
[8] Maintenance chemotherapy is effective in patients with metastatic triple negative breast cancer after first-line platinum-based chemotherapy
Chen, Yang
Zhang, Jian
Hu, Xi-Chun
Wang, Bi-Yun
Wang, Zhong-Hua
Wang, Lei-Ping
Cao, Jun
Tao, Zhong-Hua
Du, Yi-Qun
Zhao, Yan-Nan
Gong, Cheng-Cheng
Jin, Jia
ANNALS OF PALLIATIVE MEDICINE, 2020, 9 (05) : 3018 - 3027
[9] Maintenance chemotherapy is effective in patients with metastatic triple negative breast cancer after first-line platinum-based chemotherapy
Zhang, J.
Chen, Y.
Hu, X.
ANNALS OF ONCOLOGY, 2019, 30 : 132 - 132
[10] Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer phase III POLO trial
Golan, T.
Hammel, P.
Reni, M.
Van Cutsen, E.
Macarulla, T.
Hall, M.
Park, J.
Hochhauser, D.
Arnold, D.
Oh, D.
Reinacher-Shick, A.
Tortora, G.
Alguel, H.
O'Reilly, E.
McGuinness, D.
Cui, K.
Schlienger, K.
Locker, G.
Kindler, H.
ANNALS OF ONCOLOGY, 2019, 30

← 1 2 3 4 5 →